Business Context and Reporting Period
This Form 8-K is filed by Alpha Healthcare Acquisition Corp. (AHAC) on May 26, 2021, reporting events occurring on May 22, 2021, and May 26, 2021. The filing primarily concerns the ongoing business combination between AHAC and Humacyte, Inc., a clinical-stage biotechnology company developing bioengineered human tissue. The definitive Business Combination Agreement was originally executed on February 17, 2021.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for either AHAC or Humacyte. No specific financial values are provided in this document.
Material Changes and Events
- Clinical Study Results: On May 22, 2021, Humacyte presented results from clinical studies of its human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis at the Vascular Access Society of the Americas (VASA) 2021 Spring Virtual Conference.
- Award Recognition: On May 26, 2021, Humacyte received a 2021 Life Sciences Award from the Triangle Business Journal.
- Merger Status: The filing reiterates the pending merger where Hunter Merger Sub, Inc. will merge with Humacyte, with Humacyte surviving as a wholly-owned subsidiary of AHAC.
Guidance, Outlook, and Risks
Outlook and Process: The parties are preparing a registration statement on Form S-4, which will include a proxy statement/prospectus for AHAC stockholders to vote on the Business Combination. The filing emphasizes that the merger is subject to conditions, including stockholder approval.
Risks and Contingencies: The document includes extensive forward-looking statement disclaimers. Key risks identified include:
- Failure to obtain AHAC stockholder approval or satisfy other closing conditions.
- Termination of the Business Combination Agreement.
- Impact of the COVID-19 pandemic on Humacyte's business and the merger timeline.
- Uncertainty regarding the listing of AHAC's Class A Common Stock on Nasdaq post-combination.
- Potential legal proceedings and changes in applicable laws or regulations.
Investor Verification Checklist
- Verify the terms of the Business Combination in the upcoming Form S-4 Registration Statement and proxy statement/prospectus.
- Review the specific clinical data presented at the VASA 2021 conference (referenced in Exhibit 99.1) to assess Humacyte's product development progress.
- Confirm the status of AHAC stockholder voting requirements and the record date for the merger vote.
- Monitor for any updates regarding the impact of COVID-19 on the closing timeline.